University of Arizona

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Arizona sits in the top decile of US sponsors by registered trial count (#101 of 15,742 sponsors by registered trial count).

349 total trials 56 currently recruiting 213 completed early-phase tilt top decile by trial count

University of Arizona: 349 sponsored US clinical trials, 56 recruiting.

University of Arizona sponsors 349 registered US clinical trials on ClinicalTrials.gov, 56 of them currently recruiting, and 213 completed. 21 of these trials are in Phase 3-4 (later-stage) and 100 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 6 trials.

Top-decile sponsor footprint

University of Arizona ranks in the top decile of sponsors by registered trial count (#101 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

213 of 260 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

349 total, page 4 of 7

TERMINATED Phase 1

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

NCT03748303

TERMINATED NA

Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF

NCT05359965

TERMINATED NA

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

NCT04088240

COMPLETED NA

Testing the Effect of Multiple Weight Management Modalities for Chronic Disease Risk Reduction in a Clinical Setting

NCT03998878

COMPLETED Phase 4

ED-Initiated School-based Asthma Medication Supervision

NCT03952286

COMPLETED

Mitochondrial Methylation in Type 2 Diabetes

NCT04126551

TERMINATED NA

Type 2 Diabetes Prevention in Community Health Care Settings for at Risk Children and Mothers

NCT03781102

TERMINATED NA

Evaluating the Effect of Bathing Additives in Atopic Dermatitis

NCT04001855

COMPLETED Early Phase 1

IV Steroids Versus Steroids Included in Block for Orthopedic Lower Limb Surgery

NCT03855059

COMPLETED NA

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

NCT04796207

COMPLETED

Electromyography in Labor and Parturition

NCT03899493

COMPLETED Early Phase 1

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

NCT03911453

TERMINATED Phase 2

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

NCT03601507

COMPLETED NA

Oxytocin Pathways and the Health Effects of Human-Animal Interaction

NCT03852264

TERMINATED Phase 2

Study Evaluating The Role of ClO2 on Mucositis for Pt. Undergoing Head/Neck Radiotherapy

NCT03602066

COMPLETED NA

Caregivers' and Cancer Survivors' Psychological Distress & Symptom Management

NCT03743415

COMPLETED NA

Menstrual Phase and Smoking Cessation at a State Quitline

NCT03908320

COMPLETED Phase 1

Psilocybin for Treatment of Obsessive Compulsive Disorder

NCT03300947

COMPLETED Phase 2

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

NCT03714828

COMPLETED Early Phase 1

Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets

NCT03661892

COMPLETED Phase 3

Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy

NCT03657433

COMPLETED Phase 2

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

NCT03530696

COMPLETED NA

Assessment of Sleep by WHOOP in Ambulatory Subjects

NCT03692195

COMPLETED NA

Innovative Approach to Reduce Lung Cancer Stigma

NCT03750864

COMPLETED NA

Post Hysterectomy Benefits of Retained Cystoscopy Fluid

NCT03646136

COMPLETED NA

Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer

NCT04000464

TERMINATED NA

Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment

NCT03618992

COMPLETED Early Phase 1

4-methylpyrazole and Acetaminophen Metabolism

NCT03878693

COMPLETED NA

Post-chemotherapy Symptom Management SMART

NCT03494166

COMPLETED NA

Investigational Test of a New Sleep Supplement

NCT03567343

TERMINATED Early Phase 1

Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

NCT03578432

COMPLETED NA

A Guided Imagery Tobacco Cessation Intervention Delivered by a Quit Line and Website

NCT02968381

COMPLETED Phase 4

Fycompa Titration Intervals and Effects on Retention Rate

NCT03457129

COMPLETED NA

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

NCT03496844

COMPLETED NA

Evaluation of Post-Exposure Sauna Treatment of Firefighters - A Pilot Study

NCT03429348

COMPLETED NA

Probing Cortical Excitability and Cognitive Function With TMS

NCT03652012

COMPLETED NA

Improving Adherence to ACS Guidelines on Nutrition and Physical Activity in Latinas With Cancer and Their Informal Caregivers

NCT04314479

COMPLETED NA

Multi-center:The Small (14F) Percutaneous Catheter vs. Large (28-40F) Open Chest Tube for Traumatic Hemothorax (P-CAT)

NCT03546764

COMPLETED NA

Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome

NCT03665077

COMPLETED Phase 2

Postoperative subQ Pain Control for Spinal Fusion Surgery

NCT03476811

COMPLETED Phase 2

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

NCT03422536

COMPLETED NA

La Vida Buena Childhood Obesity Program

NCT03781856

COMPLETED Phase 4

Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents

NCT03279328

TERMINATED Early Phase 1

Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study

NCT03067974

COMPLETED NA

Family Routines Enhancing Adolescent Diabetes by Optimizing Management

NCT02974309

COMPLETED NA

Efficacy of the Nurtured Heart Approach to Reduce ADHD Behaviors in Children

NCT03685279

COMPLETED NA

Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)

NCT03365895

TERMINATED

Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions

NCT03198390

COMPLETED NA

Real-Time Optical Biopsy in Improving Lung Cancer Diagnosis in Patients Undergoing Lung Biopsy

NCT03376971

COMPLETED NA

Fall Prevention in Older Adults Study

NCT03176511

← Previous Page 4 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 43
Phase 2 57
Phase 3 8
Phase 4 13

What is open in the University of Arizona pipeline

56 recruiting of 349 indexed (16% open); 213 completed (61%).

Phase mix: 21 late (III/IV) vs 100 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Arizona: open-pipeline peers nationwide

Peers matched on 349 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of Arizona sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20%25% Total trials Recruiting share University of ArizonaMontefiore Medical CenterNational Institute of Mental Health (NIMH)Children's Oncology GroupOhio State University Comprehensive Cancer CenterECOG-ACRIN Cancer Research GroupGeorge Mason UniversityUniversity of California, San FranciscoNational Human Genome Research Institute (NHGRI)
University of Arizona sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Arizona sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 349 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of Arizona page

349 registered trials is a research-attention snapshot, not an endorsement of University of Arizona or any single study.

  • 56 of University of Arizona's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of Arizona studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Arizona pipeline card: 349 registered trials from official public datasets.Report a data error.